These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15330745)

  • 1. The farnesoid X receptor: a novel drug target?
    Claudel T; Sturm E; Kuipers F; Staels B
    Expert Opin Investig Drugs; 2004 Sep; 13(9):1135-48. PubMed ID: 15330745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
    Pellicciari R; Fiorucci S; Camaioni E; Clerici C; Costantino G; Maloney PR; Morelli A; Parks DJ; Willson TM
    J Med Chem; 2002 Aug; 45(17):3569-72. PubMed ID: 12166927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.
    Fiorucci S; Clerici C; Antonelli E; Orlandi S; Goodwin B; Sadeghpour BM; Sabatino G; Russo G; Castellani D; Willson TM; Pruzanski M; Pellicciari R; Morelli A
    J Pharmacol Exp Ther; 2005 May; 313(2):604-12. PubMed ID: 15644430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.
    Downes M; Verdecia MA; Roecker AJ; Hughes R; Hogenesch JB; Kast-Woelbern HR; Bowman ME; Ferrer JL; Anisfeld AM; Edwards PA; Rosenfeld JM; Alvarez JG; Noel JP; Nicolaou KC; Evans RM
    Mol Cell; 2003 Apr; 11(4):1079-92. PubMed ID: 12718892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
    Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
    Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR).
    Costantino G; Macchiarulo A; Entrena-Guadix A; Camaioni E; Pellicciari R
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1865-8. PubMed ID: 12749886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.
    Li YT; Swales KE; Thomas GJ; Warner TD; Bishop-Bailey D
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2606-11. PubMed ID: 18029909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
    Pellicciari R; Costantino G; Camaioni E; Sadeghpour BM; Entrena A; Willson TM; Fiorucci S; Clerici C; Gioiello A
    J Med Chem; 2004 Aug; 47(18):4559-69. PubMed ID: 15317466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.
    Fiorucci S; Rizzo G; Antonelli E; Renga B; Mencarelli A; Riccardi L; Morelli A; Pruzanski M; Pellicciari R
    J Pharmacol Exp Ther; 2005 Oct; 315(1):58-68. PubMed ID: 15980055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation.
    Fujino T; Une M; Imanaka T; Inoue K; Nishimaki-Mogami T
    J Lipid Res; 2004 Jan; 45(1):132-8. PubMed ID: 13130122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
    Claudel T; Staels B; Kuipers F
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2020-30. PubMed ID: 16037564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver X receptor and farnesoid X receptor as therapeutic targets.
    Rader DJ
    Am J Cardiol; 2007 Dec; 100(11 A):n15-9. PubMed ID: 18047847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.
    Landrier JF; Eloranta JJ; Vavricka SR; Kullak-Ublick GA
    Am J Physiol Gastrointest Liver Physiol; 2006 Mar; 290(3):G476-85. PubMed ID: 16269519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists.
    Zhang T; Zhou JH; Shi LW; Zhu RX; Chen MB
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2156-60. PubMed ID: 17307356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
    Pellicciari R; Gioiello A; Costantino G; Sadeghpour BM; Rizzo G; Meyer U; Parks DJ; Entrena-Guadix A; Fiorucci S
    J Med Chem; 2006 Jul; 49(14):4208-15. PubMed ID: 16821780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress in the ligands and their complex structures of farnesoid X receptor].
    Li WH; Fu J; Zheng MY; Liu GX; Tang Y
    Yao Xue Xue Bao; 2012 Jun; 47(6):704-15. PubMed ID: 22919716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression.
    Suzuki T; Tamehiro N; Sato Y; Kobayashi T; Ishii-Watabe A; Shinozaki Y; Nishimaki-Mogami T; Hashimoto T; Asakawa Y; Inoue K; Ohno Y; Yamaguchi T; Kawanishi T
    J Pharmacol Sci; 2008 Jul; 107(3):285-94. PubMed ID: 18603830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The farnesoid X receptor induces very low density lipoprotein receptor gene expression.
    Sirvent A; Claudel T; Martin G; Brozek J; Kosykh V; Darteil R; Hum DW; Fruchart JC; Staels B
    FEBS Lett; 2004 May; 566(1-3):173-7. PubMed ID: 15147890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A natural product that lowers cholesterol as an antagonist ligand for FXR.
    Urizar NL; Liverman AB; Dodds DT; Silva FV; Ordentlich P; Yan Y; Gonzalez FJ; Heyman RA; Mangelsdorf DJ; Moore DD
    Science; 2002 May; 296(5573):1703-6. PubMed ID: 11988537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.